{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:55:02Z","timestamp":1773694502397,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.3816\/clm.2005.n.039","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:10:28Z","timestamp":1221095428000},"page":"131-135","source":"Crossref","is-referenced-by-count":44,"title":["Pentostatin\/Cyclophosphamide with or Without Rituximab: An Effective Regimen for Patients with Waldenstr\u00f6m's Macroglobulinemia\/Lymphoplasmacytic Lymphoma"],"prefix":"10.3816","volume":"6","author":[{"given":"Manfred","family":"Hensel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kornacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatime","family":"Krasniqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2005.n.039_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.0954-6820.1944.tb03955.x","article-title":"Incipient myelomatosis or \u201cessential\u201d hyperglobulinemia with fibrinogenopenia: a new syndrome?","volume":"117","author":"Waldenstr\u00f6m","year":"1944","journal-title":"Acta Med Scand"},{"key":"10.3816\/CLM.2005.n.039_bib2","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.V83.6.1452.1452","article-title":"Waldenstr\u00f6m's macroglobulinemia","volume":"83","author":"Dimopoulos","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.039_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2141.2000.01918.x","article-title":"Waldenstr\u00f6m's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil","volume":"108","author":"Kyle","year":"2000","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.039_bib4","first-page":"852","article-title":"Prognostic factors in Waldenstro\u00f6m macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients","volume":"96","author":"Morel","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.039_bib5","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1200\/JCO.1994.12.12.2694","article-title":"Primary therapy of Waldenstr\u00f6m's macroglobulinemia with 2-chlorodeoxyadenosine","volume":"12","author":"Dimopoulos","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.039_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/07357909109032794","article-title":"Waldenstr\u00f6m's macroglobulinemia: long-term results with the M-2 protocol","volume":"9","author":"Case","year":"1991","journal-title":"Cancer Invest"},{"key":"10.3816\/CLM.2005.n.039_bib7","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood.V98.9.2640","article-title":"Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin- prednisone in 92 patients with Waldenstr\u00f6m macroglobulinemia in first relapse or with primary refractory disease","volume":"98","author":"Leblond","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.039_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.V98.1.41","article-title":"Prognostic factors and response to fludarabine therapy in patients with Waldenstr\u00f6m macroglobulinemia: results of United States Intergroup trial (Southwest Oncology Group S9003)","volume":"98","author":"Dhodapkar","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.039_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0609.1999.tb01848.x","article-title":"Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstr\u00f6m's macroglobulinemia","volume":"63","author":"Hellmann","year":"1999","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2005.n.039_bib10","first-page":"317","article-title":"2-Chlorodeoxyadenosine therapy in Waldenstr\u00f6m's macroglobulinaemia","volume":"36","author":"Delannoy","year":"1994","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.3816\/CLM.2005.n.039_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/oxfordjournals.annonc.a059040","article-title":"Treatment of Waldenstr\u00f6m's macroglobulinemia resistant to standard therapy with 2- chlorodeoxyadenosine: identification of prognostic factors","volume":"6","author":"Dimopoulos","year":"1995","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2005.n.039_bib12","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstr\u00f6m's macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.039_bib13","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1023\/A:1008350208019","article-title":"Rituximab therapy in Waldenstr\u00f6m's macroglobulinemia: preliminary evidence of clinical activity","volume":"10","author":"Byrd","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2005.n.039_bib14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00002371-200105000-00012","article-title":"CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstr\u00f6m's macroglobulinemia","volume":"24","author":"Treon","year":"2001","journal-title":"J Immunother"},{"key":"10.3816\/CLM.2005.n.039_bib15","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.039_bib16","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.039_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.V96.1.71","article-title":"Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies","volume":"96","author":"Flinn","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.039_bib18","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.039_bib19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1046\/j.1365-2141.2001.02959.x","article-title":"Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group","volume":"114","author":"Hallek","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.039_bib20","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1200\/JCO.2003.08.100","article-title":"Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia","volume":"21","author":"Weiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.039_bib21","unstructured":"Odaimi M, Rubin A, Ahern K, et al. Interim results of a phase II trial of therapy with cyclophosphamide\/pentostatin\/rituximab for indolent NHL and CLL. Blood 2002; 100:(Abstract #4797)."},{"key":"10.3816\/CLM.2005.n.039_bib22","first-page":"15","article-title":"Pentostatin, cyclophosphamide and rituximab (PCR therapy): a new active regimen for previously treated patients with chronic lymphocytic leukemia (CLL)","volume":"22","author":"Weiss","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2005.n.039_bib23","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.3816\/CLM.2005.n.039_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.3816\/CLM.2005.n.039_bib25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","article-title":"Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstr\u00f6m's macroglobulinemia, and mantle-cell lymphoma","volume":"17","author":"Foran","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.039_bib26","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s002770000185","article-title":"Fludarabine therapy in Waldenstr\u00f6m's macroglobulinemia","volume":"79","author":"Thalhammer-Scherrer","year":"2000","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2005.n.039_bib27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1365-2141.1998.01069.x","article-title":"Bolus administration of cladribine in the treatment of Waldenstr\u00f6m macroglobulinaemia","volume":"103","author":"Liu","year":"1998","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.039_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s002770050247","article-title":"First-line treatment of Waldenstr\u00f6m's disease with cladribine","volume":"74","author":"Fridrik","year":"1997","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2005.n.039_bib29","volume":"102","author":"Eichhorst","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.039_bib30","first-page":"2","article-title":"Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies","volume":"20","author":"Plunkett","year":"1993","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2005.n.039_bib31","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood.V94.8.2836.420k35_2836_2843","article-title":"In vitro evaluation of fludarabine in combination with cyclophosphamide and\/or mitoxantrone in Bcell chronic lymphocytic leukemia","volume":"94","author":"Bellosillo","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.039_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V80.1.29.29","article-title":"Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis","volume":"80","author":"Robertson","year":"1992","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.039_bib33","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/sj.leu.2401892","article-title":"Consolidation therapy with highdose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy","volume":"14","author":"Weiss","year":"2000","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2005.n.039_bib34","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.039_bib35","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.V88.6.2228.bloodjournal8862228","article-title":"Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation","volume":"88","author":"Provan","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.039_bib36","article-title":"Improved survival in patients with relapsed refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination","volume":"102","author":"Wierda","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.039_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0268-960X(87)90004-X","article-title":"The role of pentostatin (2\u2032-deoxycoformycin, dCF) in the management of lymphoproliferative malignancies","volume":"1","author":"Spiers","year":"1987","journal-title":"Blood Rev"},{"key":"10.3816\/CLM.2005.n.039_bib38","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.1985.3.9.1196","article-title":"Low-dose deoxycoformycin in lymphoid malignancy","volume":"3","author":"Grever","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.039_bib39","first-page":"556","article-title":"Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)","volume":"23","author":"Hochster","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2005.n.039_bib40","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cncr.11000","article-title":"Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia","volume":"97","author":"Montillo","year":"2003","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:09:37Z","timestamp":1588918177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S1557919011703808"],"URL":"https:\/\/doi.org\/10.3816\/clm.2005.n.039","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}